发明名称 AMINOESTER DERIVATIVES
摘要 Compounds of formula (I), defined herein, are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract.
申请公布号 US2015352091(A1) 申请公布日期 2015.12.10
申请号 US201514723964 申请日期 2015.05.28
申请人 CHIESI FARMACEUTICI S.P.A. 发明人 ARMANI Elisabetta;AMARI Gabriele;CAPALDI Carmelida;BLACKABY Wesley;LINNEY Ian;VAN DE POËL Hervé;BAKER-GLENN Charles;TRIVEDI Naimisha
分类号 A61K31/444;A61K31/4436;C07D409/12;A61K31/4545;C07D453/02;C07D409/14 主分类号 A61K31/444
代理机构 代理人
主权项 1. A compound of general formula (I):wherein each R1 is the same or different and is independently hydrogen, halogen, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, hydroxy, —SO2NRIRII, —CN, —NRISO2RIII, —NRIRII, —(CO)NRIRI, or —NRI(CO)RIII, and wherein each said (C1-C4) alkyl is optionally substituted by one or more groups selected from the group consisting of (C3-C7) cycloalkyl, hydroxyl, and —NRIRII and wherein each said (C1-C4) alkoxy is optionally substituted by one or more halogen atoms or (C3-C7) cycloalkyl groups, wherein: RI is hydrogen or (C1-C6) alkyl; RII is hydrogen or (C1-C6) alkyl; RIII is hydrogen or (C1-C6) alkyl; n is an integer ranging from 1 to 3; each R2 is the same or different and is independently hydrogen, halogen, (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4)haloalkyl, hydroxy, —SO2NRIRII, —CN, —NRISO2RIII, —NRIRII, —(CO)NRIRII, or —NRI(CO)RIII and wherein each said (C1-C4) alkyl is optionally substituted by one or more groups selected from the group consisting of (C3-C7) cycloalkyl, hydroxyl, and —NRIRII and wherein each said (C1-C4) alkoxy is optionally substituted by one or more halogen atoms or (C3-C7) cycloalkyl groups, wherein: RI, RII, and RIII are as defined above; m is an integer ranging from 1 to 3; each R3 and each R4 are the same or different and is independently H, (C3-C7) cycloalkylcarbonyl, (C1-C6) alkyl optionally substituted by one or more substituents selected from the group consisting of (C3-C7) cycloalkyl and (C5-C7) cycloalkenyl, (C1-C6) haloalkyl, (C3-C7) cycloalkyl, (C5-C7) cycloalkenyl, (C2-C6) alkenyl, and (C2-C6) alkynyl; or R3 and R4, together with the interconnecting atoms, form a 2,2-difluoro-1,3-dioxolane ring of formula (r) fused to the phenyl moiety which bears groups —OR3 and —OR4, wherein asterisks indicate carbon atoms shared with such phenyl ring: each R5 is the same or different and is independently CN, NO2, CF3, or halogen; k is 0 or an integer ranging from 1 to 3; x′ is 0 or 1; L1 is a bond or —(CH2)p— wherein p is an integer ranging from 1 to 4; W1 is a divalent arylene, heteroarylene, or saturated monocyclic heterocycloalkylene group; L2 is a bond, —(CH2)q— wherein q is 1 or 2, [1]—(CO)—[X]—(CH2)1-[2], or [1]—(SO2)—[X]—(CH2)t-[2], wherein [1] and [2] represent, respectively the point of attachment of group L2 to the ring W1 and to the chain nitrogen atom, and wherein [X] is a bond or a substituted or unsubstituted arylene group; t is an integer ranging from 1 to 4; W2 is an aryl or heteroaryl group; L is a bond or a —(CH2)— group; R6 is (C1-C4) alkyl, (C1-C4) alkoxy, (C1-C4) haloalkyl, and —CN, wherein each said (C1-C4) alkyl is optionally substituted by one or more groups selected from the group consisting of (C3-C7) cycloalkyl, (C1-C4) alkoxyl, and hydroxyl, or, in the alternative, when R6 is (C1-C4) alkyl, W2 is a phenyl ring, and one of R1 is an alkyl in the ortho position with respect to L, both R1 and R6 may be connected to form with W2 a condensed ring radical selected from the group consisting of 1H-cyclopropabenzene-1,1-diyl, indane-1,1-diyl (also named as 2,3-dihydro-1H-indene-1,1-diyl), indane-2,2-diyl (also named as 2,3-dihydro-1H-indene-2,2-diyl), 1,2,3,4-tetrahydronaphthalene-1,1-diyl, and 1,2,3,4-tetrahydronaphthalene-2,2-diyl; R7 is hydrogen or (C1-C4) alkyl optionally substituted by hydroxy or —NR11R12, wherein R11 and R12 are independently hydrogen or (C1-C4) alkyl, or, together with the nitrogen atom to which they are linked, R11 and R12 form a saturated heterocycloalkyl group having an additional heteroatom selected from the group consisting of 0, S, and NH; and A is a nitrogen containing group which is: a group (a) which is —(CH2)s—NR8R9 wherein s is an integer ranging from 1 to 4 and R8 and R9 are independently hydrogen or (C1-C4) alkyl; ora group (b) which is a saturated monocyclic, bicyclic or tricyclic heterocyclic ring system optionally substituted by one or two groups R10 which are at each occurrence independently (C1-C4) alkyl or benzyl; or a deuterated derivative or pharmaceutically acceptable salt thereof.
地址 Parma IT